Results 1 to 10 of about 554,772 (269)
International Journal of Molecular Sciences, 2018 Due to the clonal nature of human leukemia evolution, all leukemic cells carry the same leukemia-initiating genetic lesions, independently of the intrinsic tumoral cellular heterogeneity. However, the latest findings have shown that the mode of action of oncogenes is not homogeneous throughout the developmental history of leukemia. Studies on different
Inés González-Herrero +8 more
openaire +3 more sources
Blood Cancer Journal, 2023 In TP53 wild-type acute myeloid leukemia (AML), inhibition of MDM2 can enhance p53 protein expression and potentiate leukemic cell apoptosis. MDM2 inhibitor (MDM2i) monotherapy in AML has shown modest responses in clinical trials but combining options of
Jayastu Senapati +23 more
doaj +1 more source
The arthritis of leukemia [PDF]
Arthritis & Rheumatism, 1972 AbstractArthritis related to the primary disease was detected in 10 of 74 (13.5%) patients seen primarily for leukemia [2 of 12 patients with acute (16.6%) and 8 of 62 (12.4%) with chronic leukemia]. To these were added 18 additional patients previously diagnosed of having arthritis of leukemia.
I, Spilberg, G J, Meyer
openaire +2 more sources
Haematologica, 2016 Chronic myeloid leukemia cells acquire resistance to tyrosine kinase inhibitors through mutations in the ABL1 kinase domain. The T315I mutation mediates resistance to imatinib, dasatinib, nilotinib and bosutinib, whereas sensitivity to ponatinib remains.
Constance Baer +7 more
doaj +1 more source
Indian Journal of Hematology and Blood Transfusion, 2013 Congenital leukemia is a rare but a well-documented disease in which leukemic process is detected at birth or very shortly thereafter (Philip McCoy and Roy Overton, Commun Clin Cytom 22:85-88, 1995). These leukemias represent approximately 0.8 % of all childhood leukemias. We present a case of congenital acute myeloid leukemia manifesting from the very
Aishwarya, Raj +5 more
openaire +2 more sources
Haematologica, 2013 We conducted a phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with relapsed, refractory myeloid leukemias.
Gautam Borthakur +10 more
doaj +1 more source
Haematologica, 2012 We investigated 15,542 patients with suspected BCR-ABL1- negative myeloproliferative or myelodysplastic/myeloproliferative neoplasm (including 359 chronic myelomonocytic leukemia) by a molecular marker set.
Susanne Schnittger +9 more
doaj +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background Osteosarcoma (OS) and Ewing sarcoma (EWS) are the most common primary bone cancers in children, but acute thrombosis is poorly characterized in this population. Our study evaluated the rates of venous thromboembolism (VTE) and associated risk factors in pediatric patients with bone sarcomas treated over a 10‐year period encompassing
Sarah Kappa +8 more
wiley +1 more source
Haematologica, 2012 We analyzed 636 patients with diverse myeloproliferative neoplasms or myelodysplastic/myeloproliferative neoplasms for mutations of the Casitas B-cell lymphoma gene (CBLmut) in exons 8 and 9 and performed correlations to other genetic alterations. CBLmut
Susanne Schnittger +12 more
doaj +1 more source
Acute myeloid leukemia: current progress and future directions
Blood Cancer Journal, 2021 Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML) is occurring rapidly. Since 2017, nine agents have been approved for various indications in AML.
Hagop Kantarjian +8 more
doaj +1 more source